Lecanemab, marketed as Leqembi, is a monoclonal antibody treatment for Alzheimer’s disease that targets and removes harmful amyloid plaques while slowing cognitive decline. Scientists from VIB and KU Leuven have now uncovered exactly how it…
Continue Reading
News Source: www.sciencedaily.com
Leave a Reply